RxDoctor Payments Data

Minh Trinh

Physician Assistant · Phoenix, AZNPI 1477132116

Payments from drug & device makers

$6,133in general payments, 2019–2025

Across 348 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Novo Nordisk$824
  • AstraZeneca$654
  • Lilly USA, LLC$631
  • Amgen$527
  • Boehringer Ingelheim$406
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$6,08999%
  • Education$220%
  • Entertainment$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,133 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$6,104
Medicare patients
36
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$50,690
FarxigaDapagliflozin Propanediol32$34,628
VemlidyTenofovir Alafenamide18$25,257
OzempicSemaglutide12$19,104
VascepaIcosapent Ethyl13$13,254
Omega-3 Acid Ethyl Esters17$3,435
Atorvastatin Calcium154$1,545
Omeprazole38$1,155
Rosuvastatin Calcium25$967
Losartan Potassium114$914
Ezetimibe33$894
Fluticasone Propionate57$868
Albuterol Sulfate HfaAlbuterol Sulfate40$773
Alendronate Sodium81$660
Famotidine34$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$406$50,69035 claims
AstraZenecaFarxiga$654$34,62832 claims
GileadVemlidy$1,594$25,25718 claims
Novo NordiskOzempic$824$19,10412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →